Rość D - Search Results

1

[Some metabolic and genetic risk factors and the progression of IgA nephropathy--preliminary report].

Sulikowska B, Czarny J, Rość D, Odrowaz-Sypniewska G, Manitius J, Sliwka DM. Sulikowska B, et al. Among authors: rosc d. Pol Merkur Lekarski. 2006 Aug;21(122):132-5; discussion 136. Pol Merkur Lekarski. 2006. PMID: 17144095 Polish.

2

[Von Willebrand factor in hemodialysed patients with chronic renal failure].

Bronisz M, Rość D, Paczuski R, Nartowicz E, Bronisz A. Bronisz M, et al. Among authors: rosc d. Pol Merkur Lekarski. 2001 Jul;11(61):40-3. Pol Merkur Lekarski. 2001. PMID: 11579829 Polish.

3

[Does extracorporeal circulation during coronary artery bypass grafting damage vascular endothelium?].

Kotschy M, Zekanowska E, Rość D, Missima M, Ogorzeja W, Kotschy D. Kotschy M, et al. Among authors: rosc d. Pol Merkur Lekarski. 2003 Aug;15(86):135-9. Pol Merkur Lekarski. 2003. PMID: 14648977 Polish.

4

[Thrombomodulin, von Willebrand factor and tissue plasminogen activator in the blood plasma of obese women and men].

Rość D, Drewniak W, Kinasz-Rózycka I, Kulwas A, Michalski A. Rość D, et al. Pol Merkur Lekarski. 2003 Dec;15(90):518-20. Pol Merkur Lekarski. 2003. PMID: 15058251 Polish.

5

The role of intrinsic fibrinolytic system activation in pathogenesis of hemostasis disturbances in hemodialyzed patients with chronic renal failure.

Bronisz M, Rość D, Bronisz A, Manitius J, Nartowicz E. Bronisz M, et al. Among authors: rosc d. Ren Fail. 2004 May;26(3):223-9. doi: 10.1081/jdi-120039519. Ren Fail. 2004. PMID: 15354969 Free article.

6

[Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in children with ulcerative colitis].

Grabarczyk E, Szaflarska-Popławska A, Góralczyk K, Rość D. Grabarczyk E, et al. Among authors: rosc d. Pol Merkur Lekarski. 2006 Mar;20(117):326-8. Pol Merkur Lekarski. 2006. PMID: 16780267 Polish.

7

[Thrombinogenesis in chronic myeloproliferative syndromes].

Rość D, Kremplewska-Nalezyta E, Gadomska G, Kowalewska A, Buczkowska E. Rość D, et al. Pol Merkur Lekarski. 2006 Jun;20(120):717-20. Pol Merkur Lekarski. 2006. PMID: 17007278 Polish.

8

[Assessment of plasminogen activator inhibitor-1 and von Willebrand factor as a markers of endothelial function in patients with end-stage kidney disease after allotransplantation during a one-year follow-up].

Doroszewski W, Włodarczyk Z, Strózecki P, Manitius J, Grabarczyk E, Rość D, Odrowaz-Sypniewska G. Doroszewski W, et al. Among authors: rosc d. Pol Arch Med Wewn. 2007 May-Jun;117(5-6):213-20. Pol Arch Med Wewn. 2007. PMID: 18030870 Free article. Polish.

9

Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy.

Ruszkowska B, Gadomska G, Bielis L, Gruszka M, Góralczyk B, Rość D, Odrowąż-Sypniewska G. Ruszkowska B, et al. Among authors: rosc d. J Zhejiang Univ Sci B. 2011 Jan;12(1):12-7. doi: 10.1631/jzus.B1000106. J Zhejiang Univ Sci B. 2011. PMID: 21194181 Free PMC article. Clinical Trial.

10

[Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].

Rość D, Drewniak W, Kotschy M, Graczykowska-Koczorowska A, Raukuć D. Rość D, et al. Pol Merkur Lekarski. 1997 Jan;2(7):24-5. Pol Merkur Lekarski. 1997. PMID: 9296893 Clinical Trial. Polish.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters